Regulatory hub

UK regulatory framework for peptides. Live tracker.

Five regulators set the rules for peptides, collagen and GLP-1 medicines in the UK. We track what they are saying, in plain English, and link to the primary sources.

Last reviewed 2026-05-22. Editorial commentary, not legal advice.

AI-friendly summary · UK regulatory framework

MHRA regulates licensed UK medicines, including all GLP-1 weight-management medications (which are Prescription Only). WADA prohibits most research peptides under S0 or S2 for tested athletes. FDA decisions on Category 1 Bulk Drug Substances are widely cited but not binding in the UK. EMA opinions are typically mirrored by MHRA. ASA enforces the CAP Code on health and weight-loss claims, including the POM advertising ban.

The five jurisdictions we track

Each regulator below has a separate remit. We summarise what each one covers, link to our existing deep-dive where it exists, and flag where a deep-dive is still in build.

MHRA

Medicines and Healthcare products Regulatory Agency

UK regulator for licensed medicines and medical devices. Classifies medicines as POM, P or GSL. Acts on unlicensed medicinal product supply.

MHRA medicines classification

WADA

World Anti-Doping Agency

International anti-doping authority. Publishes the annually-updated Prohibited List. UK Anti-Doping (UKAD) enforces it on tested athletes.

WADA Prohibited List and peptides

FDA

US Food and Drug Administration

US regulator. Maintains the Category 1 Bulk Drug Substances list under section 503A. The FDA position on a research peptide is widely cited internationally, including by UK media.

Deep-dive coming soon

EMA

European Medicines Agency

EU centralised medicines authority. EMA opinions are not directly binding in the UK post-Brexit but are frequently mirrored by MHRA decisions on GLP-1 and peptide medicines.

Deep-dive coming soon

ASA

Advertising Standards Authority

UK advertising regulator. Enforces the CAP Code on health and weight-loss claims. POM medications cannot be advertised to the public.

ASA rules on weight-loss adverts

Live regulatory tracker

What UK regulators are saying about peptides and GLP-1 medicines

Last updated 2025-01-01

Per-compound UK legal status pages

Dedicated UK regulatory status pages for the most-searched peptides and GLP-1 medicines. Each one summarises the Misuse of Drugs Act position, the Psychoactive Substances Act position, the MHRA marketing authorisation position, the WADA Prohibited List position and the ASA advertising framing.

How we build this hub

We pull primary-source statements from MHRA, FDA, WADA, EMA and ASA directly. We do not paraphrase secondary reporting. Where a position has shifted, we date the entry and link to the regulator's own page so the reader can verify. Items still pending source confirmation are held back from the ticker until an editor verifies them against the regulator's own published record.

This page is editorial commentary. It is not legal advice. For binding interpretation of any regulator's position, consult the regulator directly or a qualified UK medicines lawyer.

Frequently asked questions

Who regulates peptides in the UK?

There is no single peptide regulator. MHRA regulates licensed medicines (including all GLP-1 weight-management medicines). The Office for Product Safety and Standards covers topical cosmetic peptides under the UK Cosmetics Regulation 2013. The Food Standards Agency covers ingestible collagen as a food supplement. Research peptides sold under "research use only" framing sit outside the medicines classification entirely.

Are research peptides like BPC-157 legal to buy in the UK?

BPC-157 and most other research peptides are not controlled drugs under the Misuse of Drugs Act 1971 and are not scheduled under the Psychoactive Substances Act 2016. UK retailers can sell them lawfully only when labelled "research use only, not for human or animal consumption" and when no therapeutic claim is made. The moment a seller makes a therapeutic claim, the product becomes an unlicensed medicinal product and MHRA can act.

Why can UK clinics not advertise Wegovy or Mounjaro by name?

All licensed GLP-1 weight-management medicines are Prescription Only Medicines (POM). The Human Medicines Regulations 2012 prohibit advertising POM to the public. UK clinics can describe themselves as offering weight management care or generic "GLP-1 medications" but cannot promote a specific branded medicine to consumers. ASA has upheld multiple rulings on this.

What does the WADA Prohibited List mean for a UK athlete?

UK Anti-Doping (UKAD) enforces the WADA Prohibited List on tested athletes under UKAD, British Olympic Association or international federation jurisdiction. Section S2 prohibits peptide hormones, growth factors and related substances at all times (in and out of competition). BPC-157 sits under S0. There is no detection-free or wash-out interval for these substances; metabolite detection windows extend well beyond any use period and any positive test is a violation.

How often do these regulators update their positions?

WADA publishes the Prohibited List annually, in force from 1 January each year. MHRA issues Drug Safety Updates and enforcement notices on a rolling basis. FDA reviews the Category 1 Bulk Drug Substances list approximately yearly. ASA rulings are published as cases close. The live tracker above pulls the most recent items we have surfaced.